Indeed, the single-agent activity of avelumab (PD-L1 inhibitor) [49], atezolizumab [50], and pembrolizumab [51] have shown limited activity in breast cancer patients, underscoring the need for rationally designed combination approaches [35]. The gene discussed is CD274; the disease is breast carcinoma.